Literature DB >> 7864888

Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line.

F Carlomagno1, D Salvatore, M Santoro, V de Franciscis, L Quadro, L Panariello, V Colantuoni, A Fusco.   

Abstract

The RET proto-oncogene encodes a tyrosine-kinase receptor specifically expressed in tissues of neuroectodermal origin. Recently specific point mutations of RET have been demonstrated to be responsible for the Multiple Endocrine Neoplasia type 2A and 2B and Familial Medullary Thyroid Carcinoma syndromes, characterized by the occurrence of medullary thyroid carcinomas. Here we report that a human medullary thyroid carcinoma cell line, the TT cell line, harbours a MEN2A-type mutation, specifically a cysteine to triptophan substitution at the level of the RET codon 634. This mutation is heterozygous and both normal and mutated alleles are expressed. We suggest that the TT cell line could be a useful cell system to investigate the role played by the RET oncogene in the transformation and differentiation of human thyroid C-cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7864888     DOI: 10.1006/bbrc.1995.1287

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.

Authors:  Cinzia Puppin; Cosimo Durante; Marialuisa Sponziello; Antonella Verrienti; Valeria Pecce; Elisa Lavarone; Federica Baldan; Antonio Francesco Campese; Amelie Boichard; Ludovic Lacroix; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Endocrine       Date:  2014-02-26       Impact factor: 3.633

Review 2.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

3.  Glucocorticoids differentially inhibit expression of the RET proto-oncogene.

Authors:  A Capes-Davis; S D Andrew; V J Hyland; S Twigg; D L Learoyd; T Dwight; D J Marsh; B G Robinson
Journal:  Gene Expr       Date:  1999

4.  ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.

Authors:  Claire Y Oh; Martin G Klatt; Christopher Bourne; Tao Dao; Megan M Dacek; Elliott J Brea; Sung Soo Mun; Aaron Y Chang; Tatyana Korontsvit; David A Scheinberg
Journal:  Cancer Immunol Res       Date:  2019-09-20       Impact factor: 11.151

5.  In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Authors:  Frauke Bentzien; Marcus Zuzow; Nathan Heald; Anna Gibson; Yongchang Shi; Leanne Goon; Peiwen Yu; Stefan Engst; Wentao Zhang; Donghui Huang; Lora Zhao; Valentina Vysotskaia; Felix Chu; Rajana Bautista; Belinda Cancilla; Peter Lamb; Alison H Joly; F Michael Yakes
Journal:  Thyroid       Date:  2013-09-17       Impact factor: 6.568

6.  Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.

Authors:  Chiara Tuccilli; Enke Baldini; Natalie Prinzi; Stefania Morrone; Salvatore Sorrenti; Angelo Filippini; Antonio Catania; Stefania Alessandrini; Roberta Rendina; Carmela Coccaro; Massimino D'Armiento; Salvatore Ulisse
Journal:  Endocrine       Date:  2015-07-28       Impact factor: 3.633

7.  Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates.

Authors:  R Morisi; M Celano; E Tosi; S Schenone; M Navarra; E Ferretti; G Costante; C Durante; G Botta; M D'Agostino; C Brullo; S Filetti; M Botta; D Russo
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

8.  Type 2 iodothyronine deiodinase is highly expressed in medullary thyroid carcinoma.

Authors:  Erika L Souza Meyer; Iuri M Goemann; José Miguel Dora; Marcia S Wagner; Ana Luiza Maia
Journal:  Mol Cell Endocrinol       Date:  2008-04-22       Impact factor: 4.102

9.  Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT.

Authors:  Enke Baldini; Yannick Arlot-Bonnemains; Salvatore Sorrenti; Caterina Mian; Maria R Pelizzo; Enrico De Antoni; Silvio Palermo; Stefania Morrone; Susi Barollo; Angela Nesca; Costanzo G Moretti; Massimino D'Armiento; Salvatore Ulisse
Journal:  BMC Cancer       Date:  2011-09-26       Impact factor: 4.430

10.  Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.

Authors:  Beth Apsel; Jimmy A Blair; Beatriz Gonzalez; Tamim M Nazif; Morri E Feldman; Brian Aizenstein; Randy Hoffman; Roger L Williams; Kevan M Shokat; Zachary A Knight
Journal:  Nat Chem Biol       Date:  2008-10-12       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.